Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan Graff, MD
November 24, 202512m 31s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Eichenbaum Acorns is an editorially independent series powered by Modern Retina® and hosted by David A. Eichenbaum, MD, FASRS, partner and director of research at Retina Vitreous Associates of Florida in Tampa. This Q&A-style article and podcast series explore the overlooked corners of the retina specialist profession through candid conversations with thought leaders. Eichenbaum is the German translation for oak tree, and the aim of this series is to plant acorns of insight that grow into oaks of understanding.
In this installment, Eichenbaum chats with Jordan M. Graff, MD, FACS, of Barnet Dulaney Perkins Eye Center in Phoenix, Arizona, to discuss the realities of early adoption in retina care. Graff’s experience with the port delivery system (PDS) (Susvimo; Genentech), first as an investigator and later as one of the most active commercial utilizers in the US, provides insight into the opportunities and challenges of early adoption. He has navigated both the initial excitement of innovation and the realities of setbacks, including Genentech’s October 2022 voluntary recall following septum dislodgement issues. With the July 2024 reintroduction of a revised product, Graff offers a perspective on resuming adoption post-recall.
In this installment, Eichenbaum chats with Jordan M. Graff, MD, FACS, of Barnet Dulaney Perkins Eye Center in Phoenix, Arizona, to discuss the realities of early adoption in retina care. Graff’s experience with the port delivery system (PDS) (Susvimo; Genentech), first as an investigator and later as one of the most active commercial utilizers in the US, provides insight into the opportunities and challenges of early adoption. He has navigated both the initial excitement of innovation and the realities of setbacks, including Genentech’s October 2022 voluntary recall following septum dislodgement issues. With the July 2024 reintroduction of a revised product, Graff offers a perspective on resuming adoption post-recall.